Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 10 that AKBA strengthened the intellectual property protection for its flagship therapy, Vafseo (vadadustat), after receiving a new patent listing in the FDA’s Orange Book and notification of eligibility for a five-year extension of a composition of matter patent. The additions enhance the company’s existing patent portfolio, which now includes 14 Orange Book-listed patents covering Vafseo with protection extending through 2036. These developments further support the company’s efforts to protect the long-term value and commercial potential of the therapy.

Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036

Earlier on May 7, Akebia Therapeutics, Inc. (NASDAQ:AKBA) reported its first-quarter 2026 financial results, highlighting continued progress for Vafseo and its kidney disease pipeline. Vafseo net product revenue reached $15.8 million during the quarter, while the number of patients using the therapy increased approximately 60% compared with the end of the prior quarter. The company also reported around 1,025 prescribers, representing a 28% increase from Q4 2025. Total first-quarter revenue was $53.5 million, compared with $57.3 million in the same period last year. AKBA continued advancing clinical programs, including praliciguat in FSGS and AKB-097 in rare kidney diseases, while maintaining cash resources of approximately $162.6 million as of March 31, 2026.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with kidney disease.

While we acknowledge the risk and potential of AKBA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AKBA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1